Massive Transfusion Protocol (MTP)

Definition

Massive transfusion is defined by several overlapping criteria:

Traditional: transfusion of ≥10 units of pRBCs within 24 hours (roughly equivalent to one adult blood volume)
Practical/emergency: ≥3 units pRBCs in 1 hour, or ≥4 blood components in 30 minutes
Alternative: replacement of 50% of blood volume within 3 hours, or ongoing loss >150 mL/min

The more time-sensitive definitions are more useful clinically because they allow earlier activation of the MTP.

Rationale for MTP

Acute hemorrhage means the patient is losing whole blood - not just red cells. Resuscitation with pRBCs alone depletes platelets and coagulation factors, causing dilutional and consumptive coagulopathy. MTP systematically addresses all blood components together in pre-assembled "packs," replacing the entire composition of blood loss.

Common causes requiring MTP:

Trauma (most studied population)
Ruptured aortic aneurysm
GI hemorrhage (especially with liver disease)
Obstetric emergencies (postpartum hemorrhage)
Major surgery (e.g., liver transplantation)

Triggers for MTP Activation (ACS TQIP Guidelines)

One or more of the following should prompt activation:

Trigger	Details
ABC score ≥ 2	Assessment of Blood Consumption score
Persistent hemodynamic instability	Despite initial resuscitation
Active bleeding requiring intervention	Operation or angioembolization
Blood transfusion required in trauma bay	Ongoing hemorrhage

Blood Product Ratios

The most widely adopted strategy is a 1:1:1 ratio of pRBCs : FFP : platelets, approximating reconstituted whole blood.

The landmark PROPPR trial (multicenter RCT) compared 1:1:1 vs. 2:1:1 (pRBCs:FFP:platelets). No significant difference in 24-hour or 30-day mortality overall, but the 1:1:1 group had significantly fewer deaths from exsanguination at 24 hours and higher rates of hemostasis.
Systematic reviews have not been able to mandate a single definitive ratio, but 1:1:1 remains the current standard recommendation.
A typical MTP pack at most institutions: 6 units pRBC + 6 units FFP + 1 apheresis platelet unit (equivalent to 6 whole-blood-derived platelet units), issued as a single bundle. The blood bank assembles the next pack immediately after issuing each one.

Note: "1 unit of platelets" in the 1:1:1 concept refers to whole-blood-derived units; one apheresis platelet = ~6 whole-blood-derived units.

MTP Pack Structure (Typical)

Pack 1 (and all subsequent packs):
  - 6 units pRBC
  - 6 units FFP (or thawed plasma)
  - 1 apheresis platelet unit
  ± Cryoprecipitate (fibrinogen-rich)
  ± Tranexamic acid (TXA)

Packs are issued sequentially and continuously until the clinical team signals termination.

Adjuncts to MTP

Agent	Role	Notes
Tranexamic acid (TXA)	Antifibrinolytic - reduces clot breakdown	Best within 3 hours of injury; 1g IV over 10 min then 1g over 8h (CRASH-2 protocol)
Cryoprecipitate	Rich in fibrinogen, FVIII, vWF	Given if fibrinogen <100-150 mg/dL or evidence of DIC
Fibrinogen concentrate	Targeted fibrinogen replacement	Alternative to cryo; being studied (CRYOSTAT-2 trial)
Prothrombin complex concentrate (PCC)	Replaces Factors II, VII, IX, X	Used esp. in anticoagulant reversal
rFVIIa (NovoSeven)	Last-resort hemostatic agent	Off-label; not routine
Calcium	Counteracts citrate chelation	Hypocalcemia is common - 1g IV calcium gluconate or chloride per 2-4 units pRBCs

Goal-Directed Resuscitation: TEG/ROTEM

Viscoelastic hemostatic assays - thromboelastography (TEG) and rotational thromboelastometry (ROTEM) - provide a real-time global picture of clot formation and breakdown:

Can guide targeted administration of FFP, platelets, cryoprecipitate, TXA, and factor concentrates
A 2015 systematic review could not show superiority over conventional coagulation tests (PT/INR)
A subsequent trauma study showed higher mortality with conventional coagulation-guided transfusion vs. TEG-guided - suggesting TEG/ROTEM may be beneficial, though further study is needed
Most institutions now use a hybrid approach: start with a fixed-ratio protocol, then tailor with lab results (PT, APTT, fibrinogen, TEG/ROTEM) as they become available

Laboratory-Driven Approach (Conventional Thresholds)

When shifting from protocol to lab-guided:

Parameter	Transfusion Trigger
PT/APTT > 1.5× normal	Administer FFP
Platelets < 50,000/mm³	Transfuse platelets (< 100,000 with neuro/ocular surgery or major multisystem trauma)
Fibrinogen < 100 mg/dL	Give cryoprecipitate or fibrinogen concentrate
Hb < 7-8 g/dL (or > 15% blood volume loss with ongoing hemorrhage)	Transfuse pRBCs

Special Products in Trauma Resuscitation

Uncrossmatched O Rh-negative pRBCs (or O Rh-positive for males/post-reproductive females) and thawed AB plasma (or type A plasma) should be immediately available in the ED for the first few minutes before type-specific products are ready
Type A plasma: compatible with 84% of the population (groups A and O); increasingly used because AB plasma supply is limited
Liquid plasma (never frozen, stored 2-6°C, up to 5 days): faster availability than FFP (no thawing); lower levels of labile factors after 7 days - for trauma use only
Low-titer group O whole blood: used at some centers; supplies all elements in correct physiologic ratio, but no universal whole blood exists - usually limited to 1-2 units

Complications of Massive Transfusion

Complication	Mechanism	Management
Hypothermia	Large volumes of cold blood	Warm blood products, fluid warmers, warming blankets
Hypocalcemia	Citrate in banked blood chelates ionized Ca²⁺	Calcium chloride or gluconate IV (prophylactic and therapeutic)
Hyperkalemia	K⁺ leaks from stored RBCs	Monitor K⁺ frequently; ECG changes
Hypokalemia	Citrate metabolized to bicarbonate, causing alkalosis + K⁺ shift	Monitor and replace
Metabolic acidosis	Hypoperfusion; large citrate load (especially with hepatic dysfunction)	Optimize O₂ delivery; NaHCO₃ not routinely recommended
Dilutional coagulopathy	Replacement with non-plasma fluids / pRBCs alone	MTP ratios; coag monitoring
DIC	Tissue factor release, consumptive coagulopathy (especially trauma, burns, brain injury)	Treat underlying cause; FFP, cryo, platelets
TRALI	Anti-HLA antibodies in donor plasma	Supportive; avoid FFP from multiparous donors
Transfusion reactions	Incompatibility	Standard algorithm; stop transfusion, supportive care
Citrate toxicity	Overwhelmed hepatic metabolism	Worse with hepatic dysfunction and rapid infusion

Cross-Matching Considerations

Once a patient has received approximately one blood volume of transfused products, specimens drawn after this point will contain so much donor blood that cross-matching becomes unreliable. Early specimen collection is therefore critical.

MTP Termination

The MTP is ended when:

Surgical or angiographic hemorrhage control is achieved
Physiologic parameters stabilize (HR, BP, lactate, base deficit improving)
Clinical team determines further transfusion is futile

Institutional performance improvement monitoring of MTP activations is recommended by the ACS TQIP guidelines.

Multidisciplinary Committee

An MTP should be developed with representation from:

Blood bank / transfusion service
Emergency medicine
Anesthesia
Trauma / surgery
ICU

Sources:

Rosen's Emergency Medicine, 9th Ed., Ch. 108 (Massive Transfusion Protocols)
Tintinalli's Emergency Medicine, 9th Ed., Ch. 238
Henry's Clinical Diagnosis and Management by Laboratory Methods, 23rd Ed.
Tietz Textbook of Laboratory Medicine, 7th Ed., p. 3750
ACS TQIP Massive Transfusion in Trauma Guidelines

Recent evidence:

PMID 39911088 - Cochrane systematic review (2025) on blood products for postpartum hemorrhage - MTP strategies in obstetric hemorrhage remain an area of ongoing investigation
PMID 38821531 - Systematic review (2025) on MTP in geriatric trauma - predictors and outcomes differ in older patients; standard MTP triggers may need modification in this population

This is a shared conversation. Sign in to Orris to start your own chat.